PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders – Medical Marijuana Program Connection

· Cannabis · By ReportWire
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders – Medical Marijuana Program Connection

BOSTON–(BUSINESS WIRE)–PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders Source link … Read More

MMP News Author

Source link